SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPDR S&P 500 ETF Trust is trending as escalating geopolitical tensions, specifically potential US tariffs on European economies related to Greenland and a 'Board of Peace' initiative, spark significant market uncertainty. Community discussions are rife with expectations of a market dip, though many anticipate a swift 'buy the dip' recovery, recalling past instances of market resilience to tariff-related volatility.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

The Invesco QQQ Trust is trending as renewed tariff threats and geopolitical statements from former President Trump regarding European allies and Greenland ignite market concern. While many anticipate a market dip, a strong 'buy the dip' sentiment persists among some traders, recalling past swift recoveries in the tech-heavy index.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is currently trending following recent international approvals for its cancer immunotherapies, notably in Saudi Arabia for lung cancer, alongside updated positive clinical study results. The community is enthusiastically discussing the potential of Anktiva to revolutionize cancer treatment and is vocal about perceived US FDA delays, which is fueling significant speculation around a short squeeze. Investors are expressing strong optimism regarding Dr. Soon-Shiong's strategic vision and the company's considerable growth trajectory.

United States Commodity Funds LLC - United States Natural Gas Fund

United States Natural Gas Fund, LP

United States Natural Gas Fund ($UNG) is trending as an intensifying Arctic air invasion across large parts of the US is forecast to drive a significant surge in heating demand. The community is buzzing about a potential short squeeze, given extreme short interest and the sudden shift to frigid weather, though acknowledging the commodity's notorious volatility. This immediate weather catalyst is compounded by emerging long-term demand narratives surrounding AI data centers.

BlackRock Institutional Trust Company N.A. - iShares Russell 2000 ETF

iShares Russell 2000 ETF

The iShares Russell 2000 ETF ($IWM) is a major talking point as investors debate its resilience amid ongoing discussions about potential tariffs and a highly anticipated Supreme Court ruling. Community sentiment points to a strong rotation from large-cap tech into small caps, with IWM consistently outperforming other major indices. Despite some skepticism regarding the profitability of its underlying holdings, traders are closely watching IWM's breakout performance and its implications for broader market dynamics.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is trending due to escalating U.S.-EU tariff tensions over Greenland, which has triggered a broad risk-off sentiment across the cryptocurrency market. This geopolitical uncertainty has led to substantial long liquidations, sparking community debate about Bitcoin's reliability as a safe haven asset, with some strategizing potential further declines and others viewing current levels as a buying opportunity.

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Coinbase is trending due to significant uncertainty surrounding the Digital Asset Market Clarity Act, after its CEO withdrew support over concerns about stablecoin rewards and other provisions, leading to the Senate postponing a key hearing. Community discussion reflects frustration with the stock's underperformance despite broader crypto movements, with many debating if the CEO's stance is a strategic long-term win or a short-term blow for vital revenue streams.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

SPDR Gold Shares (GLD) is trending significantly as renewed geopolitical tensions intensify, primarily driven by discussions around potential US tariffs on European countries concerning Greenland. This has sparked community debate regarding gold's role as a safe-haven asset, with many anticipating further upside amid broader uncertainty and concerns over currency debasement, while others caution about an overextended rally. The ongoing criticism of the Federal Reserve's independence adds another layer of market uncertainty supporting precious metals.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is intensely trending as a wave of bullish analyst upgrades, touting its AI-powered AXON platform and e-commerce expansion, clashes with significant recent price declines. The community is actively debating whether these drops are market manipulation and recurring short attacks ahead of anticipated strong earnings, or if the stock is facing genuine overvaluation and sector-wide headwinds.

Bitmine Immersion Technologies, Inc. is a technology company focused on acquiring, holding, and actively managing ETH as its primary treasury reserve asset. It prioritizes digital ecosystem services, such as consultancy and advisory works. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

Bitmine Immersion Technologies Inc

Bitmine Immersion Technologies is actively trending following its recent shareholder meeting, where the approval of a massive increase in authorized shares and a controversial $200 million investment in MrBeast Industries sparked widespread debate. Many investors are expressing concerns over potential dilution and a perceived deviation from the core Ethereum strategy, especially given the no-show of expected speakers and the stock's decoupling from Ethereum's performance. The community is intensely discussing whether these strategic moves represent visionary growth or significant missteps by management, led by Tom Lee.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Genprex Announces Positive Preliminary Preclinical Data from Study of GPX-002 in Type 2 Diabetic Animal Studies

Genprex Announces Positive Preliminary Preclinical Data from Study of GPX-002 in Type 2 Diabetic Animal Studies Genprex Announces Positive Preliminary Preclinical Data from Study of GPX-002 in Type 2...

Data from Genprex's Acclaim-1 Phase 1 Gene Therapy Clinical Trial Published in Clinical Lung Cancer

Data from Genprex's Acclaim-1 Phase 1 Gene Therapy Clinical Trial Published in Clinical Lung Cancer Data from Genprex's Acclaim-1 Phase 1 Gene Therapy Clinical Trial Published in Clinical Lung Cancer...

Genprex Adds Clinical Trial Site for Acclaim-1 and Acclaim-3 Lung Cancer Clinical Trials

Genprex Adds Clinical Trial Site for Acclaim-1 and Acclaim-3 Lung Cancer Clinical Trials Genprex Adds Clinical Trial Site for Acclaim-1 and Acclaim-3 Lung Cancer Clinical Trials PR Newswire AUSTIN...

Genprex Announces U.S. Patent for Reqorsa Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers

Genprex Announces U.S. Patent for Reqorsa Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers Genprex Announces U.S. Patent for Reqorsa Gene Therapy in Combination with PD-L1...

Genprex Announces European Patent Office's Intent to Grant a Patent for the Combination of Reqorsa Gene Therapy and PD-1 Antibodies to Treat Cancer

Genprex Announces European Patent Office's Intent to Grant a Patent for the Combination of Reqorsa Gene Therapy and PD-1 Antibodies to Treat Cancer Genprex Announces European Patent Office's Intent...

Genprex Announces Registered Direct Offering of up to $10.0 Million Priced At-The-Market Under Nasdaq Rules

Genprex Announces Registered Direct Offering of up to $10.0 Million Priced At-The-Market Under Nasdaq Rules Genprex Announces Registered Direct Offering of up to $10.0 Million Priced At-The-Market...

Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and...

Genprex Announces Registered Direct Offering of up to $8.1 Million Priced At-The-Market Under Nasdaq Rules

Genprex Announces Registered Direct Offering of up to $8.1 Million Priced At-The-Market Under Nasdaq Rules Genprex Announces Registered Direct Offering of up to $8.1 Million Priced At-The-Market...

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EROTC International Conference on Molecular Targets and Cancer Therapeutics

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EROTC International Conference on Molecular Targets...

&nbsp;1) Butterfly Network (NYSE: BFLY)<ul><li>Background: Butterfly Network is a digital health company pioneering accessible ultrasound technology through its handheld devices, with a mission to democratize high-quality imaging. The Butterfly iQ series has applications in multiple healthcare settings, enabling diagnostic imaging that is portable, affordable, and accessible.</li><li>The News: Butterfly Network recently partnered with HeartFocus to launch an AI-driven training app for cardiac ultrasound, compatible with Butterfly’s portable iQ devices. The app is designed to help healthcare practitioners acquire essential diagnostic skills, even in remote and underserved areas, boosting Butterfly’s appeal to health professionals globally.</li><li>What It Means: This partnership aligns with Butterfly’s vision of expanding ultrasound accessibility, particularly in resource-limited settings. By combining advanced AI-powered education with Butterfly’s handheld devices, the company positions itself as a leader in mobile diagnostics. As demand for accessible healthcare tech grows, Butterfly Network’s innovation could drive significant adoption and revenue growth.</li><li>Stock Reaction: Shares of BFLY rose 3.8%, with trading volume showing heightened interest following the announcement. Investors appear optimistic that AI integrations will boost device uptake, especially among hospitals and clinics focused on remote care.</li><li>Stocktwits Insight:&nbsp;<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_10_29_at_3_20_24_AM_903272e4bf.png" alt="Screenshot 2024-10-29 at 3.20.24 AM.png"></li></ul>&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/tech/all-systems-go-ast-spacemobile-asts-stock-throttles-up-en-route-to-the-stars/">Read now: This Space Stock is up 1,700% From $2 on a Mega Telecom Deal– is This the First of Many Contracts? or is it Headed Back to Penny Land? We Have the Inside Scoop</a>&nbsp;2) Gilat Satellite Networks (NASDAQ: GILT)<ul><li>Background: With over 35 years of experience, Gilat Satellite Networks specializes in satellite-based broadband communication solutions, catering to sectors like government, defense, and enterprise. Known for its high-quality and scalable communication systems, Gilat has a strong global reputation in satellite technology.</li><li>The News: Gilat was awarded a $4 million contract from the U.S. Department of Defense to supply DKET 3421 terminals, versatile communication hubs designed for field deployment. These terminals will enhance mission-critical communications, providing secure, mobile connectivity in challenging environments.</li><li>What It Means: This contract reinforces Gilat’s standing as a trusted defense partner, underscoring the value of its portable satellite solutions in national security contexts. Such government contracts bring stable revenue and validate Gilat’s reliability in high-stakes applications.</li><li>Stock Reaction: GILT shares rose 2.9% on above-average volume, reflecting investor confidence in Gilat’s steady pipeline of government contracts.</li><li>Stocktwits Insight: <img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_10_29_at_3_21_07_AM_975e4948a4.png" alt="Screenshot 2024-10-29 at 3.21.07 AM.png"></li></ul>&nbsp;3) Power Nickel (TSXV: PNPN)<ul><li>Background: Power Nickel, a Canadian junior exploration company, focuses on nickel and other essential metals used in electric vehicle (EV) batteries. Its primary asset, the Nisk property in Quebec, has yielded high-grade nickel and copper, attracting attention within the green tech sector.</li><li>The News: Power Nickel announced promising drill results from the Lion Zone, with intersections showing high concentrations of copper, gold, and palladium. These results enhance the project’s profile, potentially making Power Nickel a key player in sustainable, North American-based battery metals.</li><li>What It Means: With demand for nickel and battery metals on the rise, Power Nickel’s findings position it well to meet the needs of EV manufacturers seeking local, reliable sources. The results are likely to attract both investment and strategic partnerships within the green energy sector.</li><li>Stock Reaction: PNPN shares fell 2.41%, with trading volume up almost 100% from average indicating growing investor enthusiasm for Power Nickel’s expansion potential.</li><li>Stocktwits Insight: <img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_10_29_at_3_21_17_AM_62f6fd842f.png" alt="Screenshot 2024-10-29 at 3.21.17 AM.png"></li></ul>&nbsp;4) Genprex (NASDAQ: GNPX)<ul><li>Background: Genprex is a gene therapy company focused on cancer and diabetes treatments. Its flagship product, Reqorsa, aims to restore tumor-suppressor gene function in cancer patients, showing promise in treating resistant forms of lung cancer.</li><li>The News: Genprex presented positive preclinical data on Reqorsa, showcasing potential effectiveness against KRAS-resistant lung cancer, glioblastoma, and mesothelioma. This data, shared at an international symposium, underscores Reqorsa’s potential as a versatile cancer therapy.</li><li>What It Means: These findings reinforce Genprex’s pipeline credibility and could lay the groundwork for future clinical trials. If further studies replicate these results, Genprex may secure institutional investment as the therapy advances toward regulatory milestones.</li><li>Stock Reaction: GNPX shares surged 38.4% on higher-than-normal volume, as the announcement generated interest among investors.</li><li>Stocktwits Insight:&nbsp;<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_10_29_at_3_21_26_AM_dab873c609.png" alt="Screenshot 2024-10-29 at 3.21.26 AM.png"></li></ul>&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/tech/all-systems-go-ast-spacemobile-asts-stock-throttles-up-en-route-to-the-stars/">Read now: This Space Stock is up 1,700% From $2 on a Mega Telecom Deal– is This the First of Many Contracts? or is it Headed Back to Penny Land? We Have the Inside Scoop</a>&nbsp;5) Monte Rosa Therapeutics (NASDAQ: GLUE)<ul><li>Background: Monte Rosa Therapeutics is developing molecular glue degraders, which eliminate disease-causing proteins. This unique drug class has potential applications in autoimmune diseases, inflammation, and other conditions with few existing treatments.</li><li>The News: Monte Rosa announced a $150 million licensing agreement with Novartis to accelerate its VAV1-directed drug development program. The agreement provides Monte Rosa with significant financial backing to pursue its pipeline.</li><li>What It Means: Partnering with Novartis offers Monte Rosa access to substantial resources and validation for its innovative therapy approach. This collaboration could enhance Monte Rosa’s position within the biotech landscape, while boosting investor confidence.</li><li>Stock Reaction: GLUE shares jumped 93.9% as trading volume spiked, 27,000% reflecting market approval of the deal’s long-term growth potential.</li><li>Stocktwits Insight:&nbsp;<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_10_29_at_3_21_35_AM_fced9c05f9.png" alt="Screenshot 2024-10-29 at 3.21.35 AM.png"></li></ul>&nbsp;6) Atlas Lithium (NASDAQ: ATLX)<ul><li>Background: Atlas Lithium is a lithium exploration and development company working on the Neves project in Brazil’s “Lithium Valley.” With the global shift toward EVs and renewable energy storage, lithium is in high demand for battery production.</li><li>The News: Atlas secured regulatory permits to proceed with lithium extraction and processing at the Neves site. These approvals allow Atlas to develop a processing plant, positioning it to become a lithium supplier in the rapidly expanding EV battery market.</li><li>What It Means: This milestone accelerates Atlas’s journey to become a key player in the lithium supply chain. As EV adoption grows, Atlas’s Neves project may play a crucial role in meeting global lithium demand.</li><li>Stock Reaction: ATLX shares gained 24.7% on increased trading volume (5x), as investors anticipate the project’s potential impact on Atlas’s valuation.</li><li>Stocktwits Insight:&nbsp;<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_10_29_at_3_21_43_AM_6743660382.png" alt="Screenshot 2024-10-29 at 3.21.43 AM.png"></li></ul>&nbsp;7)Procept BioRobotics (NASDAQ: PRCT)<ul><li>Background: Procept BioRobotics specializes in robotic systems for urological procedures. Its AquaBeam Robotic System, a minimally invasive treatment for benign prostatic hyperplasia (BPH), has shown significant market growth.</li><li>The News: Procept reported strong Q3 earnings, driven by increased AquaBeam sales and consumables. The company raised its revenue guidance, signaling robust demand and operational growth.</li><li>What It Means: Procept’s earnings beat highlights its competitive edge in surgical robotics, particularly in the high-demand market for BPH treatment. The raised guidance reflects Procept’s confidence in continued market penetration and long-term revenue potential.</li><li>Stock Reaction: PRCT shares rose 32.3% on significant volume (6x), with investors responding positively to the improved financial outlook.</li><li>Stocktwits Insight:&nbsp;<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_10_29_at_3_22_05_AM_0dfbb455f8.png" alt="Screenshot 2024-10-29 at 3.22.05 AM.png"></li></ul>&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/tech/all-systems-go-ast-spacemobile-asts-stock-throttles-up-en-route-to-the-stars/">Read now: This Space Stock is up 1,700% From $2 on a Mega Telecom Deal– is This the First of Many Contracts? or is it Headed Back to Penny Land? We Have the Inside Scoop</a>&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.facebook.com/groups/WealthyVC">Join the Discussion on the WVC Facebook Investor Group</a><a target="_blank" rel="noopener noreferrer nofollow" href="http://www.stocktwits.com/wealthyvc">Follow us on Stocktwits</a>&nbsp;&nbsp;Have a Stock Tip or New Story Suggestion? Email us at: Invest@WealthyVC.comDisclaimer: Wealthy VC does not hold a long or short position in any of the stocks, ETFs or cryptocurrencies mentioned in this article.&nbsp;&nbsp;This article was written by an independent contributor and does not reflect the views of Stocktwits. It has not been edited for content. The information provided here is intended solely for informational and educational purposes, and should not be interpreted as investment advice. Stocktwits does not endorse the purchase or sale of any security nor does it make any claims about the financial status of any company.

Small and Micro-Cap Movers: Key News, Market Reactions, and Insider Chatter

Equity

Today’s most impactful small-cap stock updates, with exclusive rumors, insights, and analysis from StockTwits

Genprex, Inc. is a clinical-stage gene therapy company, which engages in the development of therapies for patients with cancer and diabetes. The company product is REQORSA immunogen therapy drug for non-small cell lung cancer. Its other technologies include GPX-002 gene therapy for diabetes, and ONCOPREX nanoparticle delivery system. Genprex was founded by J. Rodney Varner on April 1, 2009 and is headquartered in Austin, TX.

GNPX
Genprex Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest GNPX News

GNPXGenprex Inc